Skip to content

Evaluation of Pediatric Procedural Sedation With Rectal Chloral Hydrate or Intranasal Midazolam

Evaluation of Pediatric Procedural Sedation With Rectal Chloral Hydrate or Intranasal Midazolam - a Randomized Controlled Trial

Status
Withdrawn
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01402596
Enrollment
0
Registered
2011-07-26
Start date
2011-08-31
Completion date
2012-08-31
Last updated
2013-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Traumatic Brain Injury, Computed Tomography, Procedural Sedation

Keywords

Deep Sedation, Pediatrics, Emergency Hospital Services, Midazolam, Chloral hydrate, Randomized controlled trial

Brief summary

Thousands of children receive sedation for diagnostic and therapeutic interventions annually, and this number is expected to increase. Children are at higher risk for sedation-related complications than adults. In different scenarios, multiple drugs are used to achieve sedation, each one with particular adverse events that must be monitored and reported. Children that need CT scans for traumatic brain injuries often need sedation, without needing and IV line for that. Chloral hydrate is an hypnotic agent used since 1832 with low incidence of adverse events; however, despite its worldwide use, it's being abandoned due to bitter taste, long time of sedation onset, vomiting and mild sedation. Intranasal midazolam, on the other hand, produces high and fast concentrations on CSF with greater rates of success but probably with higher adverse events. There are no prospective studies with large series of patients using intranasal midazolam. The aim of this study is to determine if nasal midazolam is a safer approach and more effective sedative regimen when compared to rectal chloral hydrate to children undergoing CT scans.

Interventions

DRUGMidazolam

0,4 mg per kg - intranasal midazolam - once

50 mg per kg, rectal

Sponsors

University of Sao Paulo
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
DIAGNOSTIC
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
1 Months to 3 Years
Healthy volunteers
No

Inclusion criteria

* children undergoing CT scanning for TBI

Exclusion criteria

* epistaxis * suspected or confirmed skull or nasal fracture * Moderate to severe traumatic brain injury * hemodynamically unstable

Design outcomes

Primary

MeasureTime frameDescription
Adverse EventsParticipants will be followed for the duration of hospital (emergency department) stay, an expected average of 2-3 hoursSuch as hypoxemia, respiratory depression, vomiting, hypotension

Secondary

MeasureTime frameDescription
Efficacy of both drugsParticipants will be followed for the duration of hospital (emergency department) stay, an expected average of 2-3 hoursPatients vital signs and adverse events will be monitored through patient stay in the emergency department. Mean time after sedation is about three hours. Variables collected include Ramsay score for sedation. To consider hospital discharge, we will try to validate Aldrette score and compare the scores between the two arms. Mean time to onset of sedation and time of emergency department stay will also be compared as a mark of efficacy of these two drugs.

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026